Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects

Zhuo,Xian-Lu; Ling,Jun-Jun; Zhao,Hou-Yu; Zhou,Yan; Song,Yu-Feng; Tan,Ying-Hui

doi:10.3892/etm.2012.648

Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects

Authors:
- Xian-Lu Zhuo
- Jun-Jun Ling
- Hou-Yu Zhao
- Yan Zhou
- Yu-Feng Song
- Ying-Hui Tan
View Affiliations

Affiliations: Department of Stomatology, Xinqiao Hospital, Third Military Medical University, Chongqing, P.R. China , Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, P.R. China, Affiliated Hospital of Guiyang Medical College, Guiyang, P.R. China
Published online on: July 24, 2012 https://doi.org/10.3892/etm.2012.648
Pages: 748-754

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Evidence implicates cyclin D1 (CCND1) G870A polymorphisms as risk factors for various cancers. An increasing number of investigations have been conducted on the association of CCND1 G870A polymorphisms with susceptibility to oral carcinoma, and have yielded inconclusive results. The aim of the present study was to derive a more precise estimation of the correlation. Meta-analyses examining the association between CCND1 G870A polymorphisms and oral carcinoma were performed. Separate analyses on ethnicity, smoking status and control sources were also implemented. Eligible studies were identified prior to February 2012. From the overall data from 1,128 cases and 1,276 controls, no associations of CCND1 G870A polymorphisms with oral carcinoma were observed [AA vs. GG: odds ratio (OR)=1.06; 95% confidence interval (CI), 0.62‑1.82; dominant model: OR=1.04; 95% CI, 0.76-1.43; recessive model: OR=1.06; 95% CI, 0.70‑1.59]. In the subgroup analysis by ethnicity, smoking status and control sources, no significant associations of CCND1 G870A polymorphisms and oral cancer were observed for the three genetic models. Collectively, the data failed to suggest CCND1 G870A polymorphism as a low‑penetrant risk factor for developing oral carcinoma. Additional studies with large sample sizes concerning different ethnicities in different areas are required.

View Figures

View References

1	Adeyemi BF, Olusanya AA and Lawoyin JO: Oral squamous cell carcinoma, socioeconomic status and history of exposure to alcohol and tobacco. J Natl Med Assoc. 103:498–502. 2011.PubMed/NCBI
2	Li L, Psoter WJ, Buxó CJ, Elias A, Cuadrado L and Morse DE: Smoking and drinking in relation to oral potentially malignant disorders in Puerto Rico: a case-control study. BMC Cancer. 11:3242011. View Article : Google Scholar : PubMed/NCBI
3	Lin WJ, Jiang RS, Wu SH, Chen FJ and Liu SA: Smoking, alcohol, and betel quid and oral cancer: a prospective cohort study. J Oncol. 2011:5259762011.PubMed/NCBI
4	Zhuo W, Wang Y, Zhuo X, et al: CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. Cancer Invest. 27:86–95. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zhuo XL, Li Q, Zhou Y, et al: Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Arch Med Res. 40:625–634. 2009. View Article : Google Scholar : PubMed/NCBI
6	Zhou C, Zhou Y, Li J, et al: The Arg194Trp polymorphism in the X-ray repair cross-complementing group 1 gene as a potential risk factor of oral cancer: a meta-analysis. Tohoku J Exp Med. 219:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
7	Niu Y, Hu Y, Wu M, et al: CYP2E1 Rsa I/Pst I polymorphism contributes to oral cancer susceptibility: a meta-analysis. Mol Biol Rep. 39:607–612. 2012. View Article : Google Scholar : PubMed/NCBI
8	Witzel II, Koh LF and Perkins ND: Regulation of cyclin D1 gene expression. Biochem Soc Trans. 38:217–222. 2010. View Article : Google Scholar : PubMed/NCBI
9	Reis-Filho JS, Savage K, Lambros MB, et al: Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 19:999–1009. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kumar H, Vandana R and Kumar G: Immunohistochemical expression of cyclin D1 in ameloblastomas and adenomatoid odontogenic tumors. J Oral Maxillofac Pathol. 15:283–287. 2011. View Article : Google Scholar : PubMed/NCBI
11	Kaminagakura E, Werneck da Cunha I, Soares FA, Nishimoto IN and Kowalski LP: CCND1 amplification and protein overexpression in oral squamous cell carcinoma of young patients. Head Neck. 33:1413–1419. 2011. View Article : Google Scholar : PubMed/NCBI
12	Saini SS and Klein MA: Targeting Cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides. Anticancer Res. 31:3683–3690. 2011.PubMed/NCBI
13	Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
14	Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O and Ozcelik H: Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 17:2773–2781. 2008. View Article : Google Scholar : PubMed/NCBI
15	Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD and Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 11:1005–1011. 1995.PubMed/NCBI
16	Solomon DA, Wang Y, Fox SR, et al: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 278:30339–30347. 2003. View Article : Google Scholar : PubMed/NCBI
17	Sathyan KM, Nalinakumari KR, Abraham T and Kannan S: CCND1 polymorphisms (A870G and C1722G) modulate its protein expression and survival in oral carcinoma. Oral Oncol. 44:689–697. 2008. View Article : Google Scholar : PubMed/NCBI
18	Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, Golusinski W and Szyfter K: Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx. Eur Arch Otorhinolaryngol. 263:43–48. 2006. View Article : Google Scholar : PubMed/NCBI
19	Munafò MR, Clark TG and Flint J: Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 129:39–44. 2004.PubMed/NCBI
20	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
21	Nishimoto IN, Pinheiro NA, Rogatto SR, et al: Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics. Oral Oncol. 40:604–610. 2004. View Article : Google Scholar : PubMed/NCBI
22	Izzo JG, Papadimitrakopoulou VA, Liu DD, et al: Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 95:198–205. 2003. View Article : Google Scholar : PubMed/NCBI
23	Taniyama Y, Takeuchi S and Kuroda Y: Genetic polymorphisms and oral cancer. J UOEH. 32:221–236. 2010.PubMed/NCBI
24	Henriksson E, Baldetorp B, Borg A, et al: p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol. 45:300–305. 2006. View Article : Google Scholar : PubMed/NCBI
25	Liu HS, Lu HH, Lui MT, et al: Detection of copy number amplification of cyclin D1 (CCND1) and cortactin (CTTN) in oral carcinoma and oral brushed samples from areca chewers. Oral Oncol. 45:1032–1036. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kuropkat C, Venkatesan TK, Caldarelli DD, et al: Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx. 29:165–174. 2002. View Article : Google Scholar : PubMed/NCBI
27	Sartor M, Steingrimsdottir H, Elamin F, et al: Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer. 80:79–86. 1999. View Article : Google Scholar : PubMed/NCBI
28	Xu J, Gimenez-Conti IB, Cunningham JE, et al: Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer. 83:204–212. 1998. View Article : Google Scholar : PubMed/NCBI
29	Tsai MH, Tsai CW, Tsou YA, Hua CH, Hsu CF and Bau DT: Significant association of cyclin D1 single nucleotide polymorphisms with oral cancer in Taiwan. Anticancer Res. 31:227–231. 2011.PubMed/NCBI
30	Gomes CC, Drummond SN, Guimarães AL, Andrade CI, Mesquita RA and Gomez RS: P21/WAF1 and cyclin D1 variants and oral squamous cell carcinoma. J Oral Pathol Med. 37:151–156. 2008. View Article : Google Scholar : PubMed/NCBI
31	Sathyan KM, Nalinakumari KR, Abraham T and Kannan S: Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility. Oral Oncol. 42:607–613. 2006. View Article : Google Scholar : PubMed/NCBI
32	Holley SL, Matthias C, Jahnke V, Fryer AA, Strange RC and Hoban PR: Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol. 41:156–160. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wong YK, Lin SC, Chang CS, et al: Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med. 32:265–270. 2003. View Article : Google Scholar : PubMed/NCBI
34	Matthias C, Branigan K, Jahnke V, et al: Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 4:2411–2418. 1998.PubMed/NCBI
35	Thakkinstian A, McElduff P, D’Este C, Duffy D and Attia J: A method for meta-analysis of molecular association studies. Stat Med. 24:1291–1306. 2005. View Article : Google Scholar : PubMed/NCBI
36	Shen C, Sun H, Sun D, et al: Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 126:763–770. 2011. View Article : Google Scholar : PubMed/NCBI
37	Zhang LQ, Wang J, Shang JQ, et al: Cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Int J Colorectal Dis. 26:1249–1255. 2011. View Article : Google Scholar
38	Sergentanis TN and Economopoulos KP: Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep. 38:4955–4963. 2011. View Article : Google Scholar : PubMed/NCBI
39	Yuan L, Gu X, Shao J, Wang M, Zhu Q and Zhang Z: Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol. 29:611–617. 2010. View Article : Google Scholar : PubMed/NCBI
40	Ni J, Wang M, Wang M, Fu S, Zhou D, Zhang Z and Han S: CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis. J Cancer Res Clin Oncol. 137:489–494. 2011. View Article : Google Scholar : PubMed/NCBI
41	Tang C, Wang Z, Yu J, Wu Y, Zhu Z and Chen N: CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis. Med Oncol. 28:1319–1324. 2011. View Article : Google Scholar : PubMed/NCBI
42	Hsia TC, Liu CJ, Lin CH, et al: Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients. Anticancer Res. 31:3601–3605. 2011.PubMed/NCBI
43	Gautschi O, Hugli B, Ziegler A, et al: Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 51:303–311. 2006. View Article : Google Scholar : PubMed/NCBI